Competitive Salary: EMBL: Project Leader - Model Organism Genomics Location: Cambridge, Cambridgeshire, England

Funding Opportunity PAR-19-369 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC will be considered not responsive to this FOA and will not be accepted.

Funding Opportunity PAR-19-365 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the latter years of their award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

Funding Opportunity RFA-HL-20-006 from the NIH Guide for Grants and Contracts. The purpose of this program is to provide continued support to Transition Scholars who have successfully matriculated through the NIH Stimulating Access to Research in Residency (StARR) R38 program as resident investigators, and who demonstrate potential and continued interest in pursuing careers as clinician-investigators. Awards will provide 12-24 months of mentored research and career development support to those individuals who completed R38 research training, have secured a clinical fellowship or early-career faculty appointment (as instructor or assistant professor for less than 40 months at the time of submission or resubmission), and propose a strong research and career development plan towards continued, successful research careers.

Funding Opportunity PAR-19-368 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.

Funding Opportunity RFA-HL-20-028 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

Funding Opportunity RFA-HL-20-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Funding Opportunity RFA-HL-20-024 from the NIH Guide for Grants and Contracts. This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

Funding Opportunity RFA-HL-20-023 from the NIH Guide for Grants and Contracts. This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Funding Opportunity RFA-HL-20-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This FOA is part of a suite of NHLBI Catalyze program to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.

Negotiable: Paramount Recruitment: Senior Platform Programmer - Bioinformatics Cambridge This is a great opportunity for an experienced programmer/developer to be involved in the techni Cambridge, England

Funding Opportunity PAR-19-370 from the NIH Guide for Grants and Contracts. The NIDCR Small Grant Program for New Investigators (R03) supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator initiated Research Project Grant (R01) or equivalent application.

Notice NOT-DK-19-022 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-367 from the NIH Guide for Grants and Contracts. The Maximizing Investigators' Research Award (MIRA) provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this program will: Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively; Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies; More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs; Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research; Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. This FOA allows both new applications from eligible NIGMS-funded investigators and renewal applications from current established and early-stage MIRA grantees.

EUR 50,000 to 60,000 : CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: The Biomedical Sequencing Facility is Austria’s leading technology platform and service provider for genomics in biomedicine Vienna (AT)

Funding Opportunity PAR-19-366 from the NIH Guide for Grants and Contracts. The purpose of the Institutional Research and Academic Career Development Award (IRACDA) Program is to develop a diverse pool of well-trained scientists available to address the nation's biomedical research agenda. The program requires effective partnerships between a research-intensive institution and a teaching-intensive partner institution that has a historical mission or a demonstrated commitment to educating students from groups underrepresented in the biomedical research workforce. The IRACDA program provides support for a mentored postdoctoral research training experience at the research-intensive institution and funding for the IRACDA scholars to develop critical teaching and mentoring skills at a partner institution. The primary goals of the IRACDA program are to develop a diverse pool of well-trained biomedical scientists who have the necessary knowledge and skills to pursue independent academic careers and to enhance science educational offerings at partner institutions. This Funding Opportunity Announcement (FOA) does not allow appointed scholars to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

Notice NOT-HS-19-020 from the NIH Guide for Grants and Contracts

Notice NOT-MH-19-039 from the NIH Guide for Grants and Contracts

Notice NOT-TR-19-027 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-026 from the NIH Guide for Grants and Contracts